Health care had a strong day in Hong Kong and Mainland China as Cansino Biologics gained +17% after announcing strong phase 3 coronavirus clinical trials.

Health care had a strong day in Hong Kong and Mainland China as Cansino Biologics gained +17% after announcing strong phase 3 coronavirus clinical trials.